Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone

Rosa Karemaker, Cobi J. Heijnen, Sylvia Veen, Wim Baerts, Janny Samsom, Gerard H.A. Visser, Annemieke Kavelaars, Lorenz J.P. Van Doornen, Frank Van Bel

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Neonatal dexamethasone (DEX) for chronic lung disease is associated with adverse outcome. We compared behavioral and motor development at school age of children who neonatally received DEX to children neonatally treated with hydrocortisone (HC) in a retrospective matched cohort study. DEX- and HC-treated groups matched for gestational age, birth weight and year, gender, and severity of respiratory distress syndrome were compared with a reference group (REF) and a group treated only antenatally with betamethasone (BMETH). REF and BMETH groups had a higher gestational age and less severe respiratory distress syndrome. From 192 children (DEX, n = 46; HC, n = 52; REF, n = 43; BMETH, n = 51), the Child Behavioral Checklists from parents and teachers (Teacher's Report Form) and the Movement Assessment Battery for Children to assess neuromotor function were analyzed. DEX girls had a poorer performance on nearly all behavioral scales of the Teacher's Report Form compared with HC girls. DEX boys did not differ from HC boys. The HC boys or girls did not differ from the REF or BMETH groups. Neuromotor development was poorer in DEX than the BMETH and REF groups. The HC group did not differ from REF and BMETH groups. We suggest that neonatal HC may be a "safer" alternative for DEX for the treatment of CLD.

Original languageEnglish (US)
Pages (from-to)745-750
Number of pages6
JournalPediatric research
Volume60
Issue number6
DOIs
StatePublished - Dec 1 2006

Fingerprint

Betamethasone
Dexamethasone
Lung Diseases
Hydrocortisone
Chronic Disease
Therapeutics
Gestational Age
Checklist
Birth Weight
Cohort Studies
Research Design
Parents

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. / Karemaker, Rosa; Heijnen, Cobi J.; Veen, Sylvia; Baerts, Wim; Samsom, Janny; Visser, Gerard H.A.; Kavelaars, Annemieke; Van Doornen, Lorenz J.P.; Van Bel, Frank.

In: Pediatric research, Vol. 60, No. 6, 01.12.2006, p. 745-750.

Research output: Contribution to journalArticle

Karemaker, Rosa ; Heijnen, Cobi J. ; Veen, Sylvia ; Baerts, Wim ; Samsom, Janny ; Visser, Gerard H.A. ; Kavelaars, Annemieke ; Van Doornen, Lorenz J.P. ; Van Bel, Frank. / Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. In: Pediatric research. 2006 ; Vol. 60, No. 6. pp. 745-750.
@article{545a8c9aff1c4c9da14d024f739ccc7f,
title = "Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone",
abstract = "Neonatal dexamethasone (DEX) for chronic lung disease is associated with adverse outcome. We compared behavioral and motor development at school age of children who neonatally received DEX to children neonatally treated with hydrocortisone (HC) in a retrospective matched cohort study. DEX- and HC-treated groups matched for gestational age, birth weight and year, gender, and severity of respiratory distress syndrome were compared with a reference group (REF) and a group treated only antenatally with betamethasone (BMETH). REF and BMETH groups had a higher gestational age and less severe respiratory distress syndrome. From 192 children (DEX, n = 46; HC, n = 52; REF, n = 43; BMETH, n = 51), the Child Behavioral Checklists from parents and teachers (Teacher's Report Form) and the Movement Assessment Battery for Children to assess neuromotor function were analyzed. DEX girls had a poorer performance on nearly all behavioral scales of the Teacher's Report Form compared with HC girls. DEX boys did not differ from HC boys. The HC boys or girls did not differ from the REF or BMETH groups. Neuromotor development was poorer in DEX than the BMETH and REF groups. The HC group did not differ from REF and BMETH groups. We suggest that neonatal HC may be a {"}safer{"} alternative for DEX for the treatment of CLD.",
author = "Rosa Karemaker and Heijnen, {Cobi J.} and Sylvia Veen and Wim Baerts and Janny Samsom and Visser, {Gerard H.A.} and Annemieke Kavelaars and {Van Doornen}, {Lorenz J.P.} and {Van Bel}, Frank",
year = "2006",
month = "12",
day = "1",
doi = "10.1203/01.pdr.0000246200.76860.de",
language = "English (US)",
volume = "60",
pages = "745--750",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone

AU - Karemaker, Rosa

AU - Heijnen, Cobi J.

AU - Veen, Sylvia

AU - Baerts, Wim

AU - Samsom, Janny

AU - Visser, Gerard H.A.

AU - Kavelaars, Annemieke

AU - Van Doornen, Lorenz J.P.

AU - Van Bel, Frank

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Neonatal dexamethasone (DEX) for chronic lung disease is associated with adverse outcome. We compared behavioral and motor development at school age of children who neonatally received DEX to children neonatally treated with hydrocortisone (HC) in a retrospective matched cohort study. DEX- and HC-treated groups matched for gestational age, birth weight and year, gender, and severity of respiratory distress syndrome were compared with a reference group (REF) and a group treated only antenatally with betamethasone (BMETH). REF and BMETH groups had a higher gestational age and less severe respiratory distress syndrome. From 192 children (DEX, n = 46; HC, n = 52; REF, n = 43; BMETH, n = 51), the Child Behavioral Checklists from parents and teachers (Teacher's Report Form) and the Movement Assessment Battery for Children to assess neuromotor function were analyzed. DEX girls had a poorer performance on nearly all behavioral scales of the Teacher's Report Form compared with HC girls. DEX boys did not differ from HC boys. The HC boys or girls did not differ from the REF or BMETH groups. Neuromotor development was poorer in DEX than the BMETH and REF groups. The HC group did not differ from REF and BMETH groups. We suggest that neonatal HC may be a "safer" alternative for DEX for the treatment of CLD.

AB - Neonatal dexamethasone (DEX) for chronic lung disease is associated with adverse outcome. We compared behavioral and motor development at school age of children who neonatally received DEX to children neonatally treated with hydrocortisone (HC) in a retrospective matched cohort study. DEX- and HC-treated groups matched for gestational age, birth weight and year, gender, and severity of respiratory distress syndrome were compared with a reference group (REF) and a group treated only antenatally with betamethasone (BMETH). REF and BMETH groups had a higher gestational age and less severe respiratory distress syndrome. From 192 children (DEX, n = 46; HC, n = 52; REF, n = 43; BMETH, n = 51), the Child Behavioral Checklists from parents and teachers (Teacher's Report Form) and the Movement Assessment Battery for Children to assess neuromotor function were analyzed. DEX girls had a poorer performance on nearly all behavioral scales of the Teacher's Report Form compared with HC girls. DEX boys did not differ from HC boys. The HC boys or girls did not differ from the REF or BMETH groups. Neuromotor development was poorer in DEX than the BMETH and REF groups. The HC group did not differ from REF and BMETH groups. We suggest that neonatal HC may be a "safer" alternative for DEX for the treatment of CLD.

UR - http://www.scopus.com/inward/record.url?scp=33751211199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751211199&partnerID=8YFLogxK

U2 - 10.1203/01.pdr.0000246200.76860.de

DO - 10.1203/01.pdr.0000246200.76860.de

M3 - Article

C2 - 17065571

AN - SCOPUS:33751211199

VL - 60

SP - 745

EP - 750

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -